Titan Provides Additional Positive Results in Confirmatory Phase 3 Trial of Probuphine. Pfizer wins Viagra patent-protection case. Print E-mail
By Staff and Wire Reports   
Tuesday, 16 August 2011 19:13
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 12, 2011.

Titan Pharmaceuticals, Inc. (OTC:TTNP) announced additional positive results from its Phase 3 placebo - and active drug - controlled confirmatory clinical study of Probuphine, evaluating the safety and efficacy of its investigational drug in treating patients with opioid dependence.

Probuphine was found to be well tolerated and Probuphine treatment resulted in a significant improvement in the global severity of opioid dependence (p = 0.0003) and overall patient improvement (p = 0.0002) versus placebo, as assessed by clinicians. The additional data analyses also confirm Probuphine's non-inferiority to the approved drug SUBOXONE.

These findings build upon the clinically meaningful and statistically significant top line data announced by Titan in July 2011, which confirmed the efficacy of Probuphine compared to placebo for two primary endpoints (p < 0.0001 for both). Titan has been invited to present these findings during a plenary session on September 10 and in a poster presentation on September 8 at the 13th annual meeting of the International Society of Addiction Medicine (ISAM) in Oslo, Norway.

---

Drugmaker Pfizer, Inc. (NYSE:PFE) as it tried to fend off a generic version of its erectile-dysfunction drug Viagra in a patent-protection lawsuit.  The suit pitted Pfizer and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA),  two of the world's biggest drugmakers, against each other. Pfizer is the global leader in pharmaceutical sales, and Teva leads the pack in generic drugs, which now account for about 75 percent of the market.

"This court finds that Teva has not shown by clear and convincing evidence" that the patent is invalid, according to the ruling issued Friday and made public Monday by U.S. District Judge Rebecca Beach Smith in the Eastern District of Virginia.

Teva could appeal, and Pfizer has similar suits pending against other generic manufacturers, which are hoping to start selling their versions in March. If Pfizer prevails in those legal battles, Viagra would be protected from generic competition through 2019.

Pfizer sold $965 million worth of Viagra in just the first half of 2011, according to its second-quarter filing with the Securities and Exchange Commission.  Viagra is Pfizer's sixth-best-selling drug. Lipitor is first, and it loses patent protection at the end of November.

Like other manufacturers, Pfizer has fretted about revenue declines in the future as high-profit drugs lose exclusivity, so this stems that tide for a bit.

If Teva had won the suit, patent protection would have disappeared in March, and the revenue would have dropped.

"We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction," Amy Schulman, executive vice president and general counsel for Pfizer, said in a statement Monday.



Also Tuesday:



ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, has announced its second quarter 2011 investor conference call and the recent progress in its MuGard program.  

Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors has approved an increase in the Company's quarterly cash dividend from 42 cents per share to 49 cents per share.

CNS Response, Inc. (OTCBB: CNSO) today announced that it has executed agreements with two major Southern California psychiatric provider groups, with a combined total of 23 physicians servicing most major managed care plans.

CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses, announced its financial results for the second quarter of fiscal 2011.

GeneLink, Inc. (OTCBB: GNLK), a leading consumer genomics biotech company, today reported financial results for the quarter ended June 30th, 2011.

GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

PharmAthene, Inc. (NYSE Amex:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company has been awarded a $5.7 million contract under a Department of Defense (DoD) Broad Agency Announcement for studies directed at the development of an advanced expression system for the bioproduction of its nerve agent medical countermeasure program.

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cell-based virology assays, announced today that it has received the CE Mark for its Sofia® Fluorescent Immunoassay Analyzer and for its Sofia® Influenza A+B Fluorescent Immunoassay (FIA).

Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries, announced that the company will be starting a potentially lucrative relationship with a major player in cold chain development.

3SBio Inc. (NASDAQ:SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter and first half ended June 30, 2011.

TheDirectory.com, Inc. (PINKSHEETS: EYSM) today announced that it has received notice from FINRA that the ticker symbol "SEEK" has been assigned to the Company; effective Wednesday, August 17th the Company will open for trading under the new ticker symbol "SEEK".

Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the second quarter ended June 30, 2011.

University General Health System, Inc. (OTCQB: UGHS) (PINKSHEETS: UGHS), a diversified, integrated multi-specialty health delivery system, today announced its financial results for the second quarter and six months ended June 30, 2011.

Zurvita Holdings, Inc. (OTCBB: ZRVT) ("Zurvita" or the "Company"), a dynamic network marketing company offering turn-key solutions for high-quality consumer and business products and services, announced that it previewed its 'Zeal Fit & Free Weight Management Program' to Zurvita consultants at its Champions Weekend Conference held in Garden Grove, CA July 28th through July 31st, 2011.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter